Hikma and Sesen Bio have struck a deal that will see Hikma distribute the Vicineum brand in the MENA region.
Hikma and Sesen Bio have struck an exclusive deal that will see Hikma distribute Sesen’s Vicineum (oportuzumab monatox) branded cancer treatment, a locally administered fusion protein, in the Middle East and North Africa region.
“The licensing agreement provides Hikma with exclusive rights to commercialize and distribute Vicineum in the MENA region for the treatment...
Melinta Therapeutics has prevailed at the Federal Circuit in a patent dispute over its reformulated intravenous antibiotic Minocin, with the appeals court upholding both infringement and validity and leaving Nexus Pharmaceuticals barred from launching a generic until 2031.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains
A look at new research on the cardiovascular effects of ADHD medications and what it means for clinical care. This article explores the latest clinical and epidemiological research on the cardiovascular effects of medications commonly prescribed for ADHD, examining potential heart-related risks, underlying mechanisms, and their implications for patient safety, clinical decision-making, and long-term treatment strategies across diverse age groups and risk profiles.
